Literature DB >> 32880041

Radioembolization for Hepatocellular Carcinoma in Downstaging and Bridging for Liver Transplantation.

Ramazan Kutlu1, Sinan Karatoprak2.   

Abstract

PURPOSE: Hepatocellular carcinoma (HCC) is the most common primary liver tumor. Only about one third of them are eligible for curative treatments like liver transplantation. Various interventional oncologic treatment options could be employed for some of the HCC patients outside the acceptable liver transplantation criteria to make them suitable for transplantation by downstaging and keeping them inside the criteria by bridging to transplantation.
METHODS: We reviewed the literature by the terms of downstaging and bridging therapy for liver transplantation.
RESULTS: About only 30% of the patients are suitable for curative procedures like transplantation at the time of diagnosis of HCC. Even the Milan Criteria is expanded or new criteria are defined, still there are many patients who need downstaging to be eligible for transplantation. There are different procedures in interventional oncology for primary and metastatic liver lesions. Radioembolization (RE) is one of the locoregional therapies which is more effective than others for downstaging and bridging for liver transplantation.
CONCLUSION: Downstaging by RE is an effective and reasonable method for unresectable HCC cases initially beyond established criteria for liver transplantation by selecting suitable and favorable tumor biology.

Entities:  

Keywords:  Downstaging; Hepatocellular carcinoma; Liver transplant; Radioembolization

Mesh:

Substances:

Year:  2020        PMID: 32880041     DOI: 10.1007/s12029-020-00492-y

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  4 in total

1.  Artificial Intelligence Algorithm in Classification and Recognition of Primary Hepatic Carcinoma Images under Magnetic Resonance Imaging.

Authors:  Zehua He; Qingqiang Huang; Yingyang Liao; Xiaojie Xu; Qiulin Wu; Yuanle Nong; Ningfu Peng; Wanrong He
Journal:  Contrast Media Mol Imaging       Date:  2022-06-07       Impact factor: 3.009

2.  Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases.

Authors:  Ying Zhu; Jianguo Xu; Wei Hu; Fang Wang; Yan Zhou; Wei Gong; Wen Xu
Journal:  Aging (Albany NY)       Date:  2021-06-03       Impact factor: 5.682

3.  Does timing matter in radiotherapy of hepatocellular carcinoma? An experimental study in mice.

Authors:  Soha A Hassan; Amira A H Ali; Dennis Sohn; Ulrich Flögel; Reiner U Jänicke; Horst-Werner Korf; Charlotte von Gall
Journal:  Cancer Med       Date:  2021-09-20       Impact factor: 4.452

Review 4.  SIRT in 2025.

Authors:  Francesca Romana Ponziani; Francesco Santopaolo; Antonio Gasbarrini; Roberto Iezzi; Alessandro Posa; Maurizio Pompili; Alessandro Tanzilli; Marta Maestri; Maria Pallozzi; Francesca Ibba; Riccardo Manfredi
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-08       Impact factor: 2.797

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.